In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alchemab Is Bringing A New Meaning To Patient-Centered Care

British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience

Executive Summary

Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.

You may also be interested in...



Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Advanz Zeroes In On Innovative Assets And M&A

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Sun Pharma Reinforces Position As Indian Industry Leader

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV146723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel